BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1853147)

  • 21. Gallstone formation and dissolution.
    Morrissey KP
    Major Probl Clin Surg; 1982; 16():61-100. PubMed ID: 7054618
    [No Abstract]   [Full Text] [Related]  

  • 22. The cholesterol saturation of bile and its reduction by chenodeoxycholic acid in massively obese patients.
    Whiting MJ; Hall JC; Iannos J; Roberts HG; Watts JM
    Int J Obes; 1984; 8(6):681-8. PubMed ID: 6533091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleation time, cholesterol saturation index, and biliary bile acid pattern. A comparison in responders and nonresponders to systemic litholysis with bile acids.
    Janowitz P; Wechsler JG; Janowitz A; Kuhn K; Swobodnik W; Ditschuneit H
    Scand J Gastroenterol; 1991 Apr; 26(4):367-73. PubMed ID: 2034990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the effects of chenodeoxycholic and ursodeoxycholic acid on biliary lipid secretion and bile acid synthesis in patients with gallstones.
    von Bergmann K; Epple-Gutsfeld M; Leiss O
    Gastroenterology; 1984 Jul; 87(1):136-43. PubMed ID: 6724256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Changes in the pattern of serum biliary acids and lipoprotein picture during therapy with biliary acids in cholesterol lithiasis].
    Di Mario F; Angonese C; Del Favero G; Aggio L; Meggiato T; Scalon P; Basso D; Plebani M; Burlina A; Naccarato R
    G Clin Med; 1990; 71(6-7):435-41. PubMed ID: 2258026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials.
    May GR; Sutherland LR; Shaffer EA
    Aliment Pharmacol Ther; 1993 Apr; 7(2):139-48. PubMed ID: 8485266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of response to ursodeoxycholic acid for gallstone dissolution.
    Bateson MC; Hill A; Bouchier IA
    Digestion; 1980; 20(5):358-64. PubMed ID: 7390061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.
    Iser JH; Maton PN; Murphy GM; Dowling RH
    Br Med J; 1978 Jun; 1(6126):1509-12. PubMed ID: 656777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the effects of an equal dose of 15 mg/kg/day of chenodeoxycholic and ursodeoxycholic acid on the composition of biliary lipids and acids in the bile in radiotransparent biliary lithiasis].
    Garrido G; Breto M; Alegre B; Pérez Aguilar F; Berenguer J
    Rev Esp Enferm Apar Dig; 1983 Oct; 64(4):261-9. PubMed ID: 6658120
    [No Abstract]   [Full Text] [Related]  

  • 30. Liquid crystal formation in ursodeoxycholate-rich human gallbladder bile.
    Igimi H; Asakawa S; Watanabe D; Shimura H
    Gastroenterol Jpn; 1983 Apr; 18(2):93-7. PubMed ID: 6852442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combined therapy with chenodeoxycholic acid and ursodeoxycholic acid of radiolucent biliary lithiasis].
    Pérez Aguilar F; Breto M; del Val A; Berenguer J
    An Med Interna; 1989 Mar; 6(3):119-24. PubMed ID: 2491184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible?
    Iser JH; Murphy GM; Dowling RH
    Gut; 1977 Jan; 18(1):7-15. PubMed ID: 838406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of diet on bile acid kinetics and biliary lipid secretion in gallstone patients treated with ursodeoxycholic acid.
    Frenkiel PG; Lee DW; Cohen H; Gilmore CJ; Resser K; Bonorris GG; Marks JW; Schoenfield LJ
    Am J Clin Nutr; 1986 Feb; 43(2):239-50. PubMed ID: 3004189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chenodeoxycholic acid and ursodeoxycholic acid administration on acyl-CoA: cholesterol acyltransferase activity in human liver.
    Abate N; Carubbi F; Bozzoli M; Bertolotti M; Farah I; Rosi A; Carulli N
    Ital J Gastroenterol; 1994; 26(6):287-93. PubMed ID: 7949265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nucleation time and growth time in patients with cholesterol gallstone--factors affecting nucleation time and growth time and effect of UDCA and CDCA].
    Nomura Y
    Nihon Shokakibyo Gakkai Zasshi; 1989 May; 86(5):1103-13. PubMed ID: 2795947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group.
    Petroni ML; Jazrawi RP; Pazzi P; Lanzini A; Zuin M; Pigozzi MG; Fracchia M; Galatola G; Alvisi V; Heaton KW; Podda M; Northfield TC
    Aliment Pharmacol Ther; 2001 Jan; 15(1):123-8. PubMed ID: 11136285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of radiolucent gallstones with CDCA or UDCA. A multicenter trial.
    Polli EE; Bianchi PA; Conte D; Sironi L
    Digestion; 1981; 22(4):185-91. PubMed ID: 7030835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleation time of gall bladder bile in gall stone patients: influence of bile acid treatment.
    Sahlin S; Ahlberg J; Angelin B; Reihnér E; Einarsson K
    Gut; 1991 Dec; 32(12):1554-7. PubMed ID: 1773966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical management of cholesterol gallstones.
    Abate MA
    Drug Intell Clin Pharm; 1986 Feb; 20(2):106-15. PubMed ID: 3512222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone.
    Podda M; Zuin M; Battezzati PM; Ghezzi C; de Fazio C; Dioguardi ML
    Gastroenterology; 1989 Jan; 96(1):222-9. PubMed ID: 2642440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.